What's narcolepsy type 1?
Narcolepsy type 1 (NT1) is defined by the combination of cataplexy and a low level of the wake-promoting neuropeptide orexin/hypocretin in the cerebrospinal fluid (typically under 110 pg/mL). It is not a simple inherited disease: current evidence points to a multifactorial, immune-mediated loss of the hypothalamic orexin-producing neurons, shaped by genetic predisposition (a strong association with the HLA-DQB1*06:02 tissue type) and environmental triggers. The HLA link is a susceptibility marker, not a Mendelian cause, so NT1 is not passed down in a predictable pattern.
| Also indexed as | ORPHA:2073, MONDO:0016158 |
|---|---|
| Features mapped | 9 |
| Treatments mapped | 9 |
| Published sources | 7 |
| Last reviewed | 2026-08-04 |
Signs and symptoms
Sleep apnea
obstructive sleep apnea is more common in adults with narcolepsy type 1 than in the general population, and the two can occur together.
Sleep disturbance
Although daytime sleepiness dominates, night-time sleep is often fragmented and disrupted, so total sleep is not actually increased.
Hypnagogic hallucination
Vivid, dream-like hallucinations can occur while drifting off to sleep (hypnagogic) or on waking (hypnopompic), and can be frightening because they feel real.
Cataplexy
Cataplexy is the feature that defines type 1: sudden, brief episodes of muscle weakness triggered by strong emotions such as laughter, so the knees buckle, the jaw or head drops, or the person collapses while staying fully awake. It reflects REM-sleep muscle paralysis intruding into wakefulness and, together with a low orexin level, distinguishes type 1 from type 2.
Excessive daytime somnolence
Overwhelming daytime sleepiness is usually the first and most disabling symptom: an irresistible need to sleep and sudden sleep attacks during the day, even after a full night's sleep.
Hypnopompic hallucination
Vivid, dream-like hallucinations as a person wakes up (hypnopompic hallucinations) are a common feature of narcolepsy type 1. Like the similar hallucinations on falling asleep, they happen because dreaming REM sleep intrudes into wakefulness.
Sleep paralysis
Sleep paralysis is a brief inability to move or speak while falling asleep or waking up, another sign of REM-sleep phenomena spilling into the transition between sleep and wakefulness.
Abnormal rapid eye movement sleep
People with the condition enter REM (dream) sleep abnormally fast. On a daytime nap study, REM appears within minutes of falling asleep, which is a key supporting test finding.
Low CSF hypocretin-1 (orexin deficiency)
Narcolepsy type 1 is caused by the loss of brain cells that make hypocretin (also called orexin), a chemical that keeps us awake and stabilizes sleep. Measuring a low level of hypocretin-1 in the spinal fluid is one of the most specific ways to confirm the diagnosis.
How it is diagnosed
Narcolepsy type 1
Diagnosed using: Multiple sleep latency test (MSLT).
“…systematically measuring CSF-HCRT1 in the presence of a negative PSG-MSLT identifies about 10% additional NT1…”
Narcolepsy type 1
Diagnosed using: Sleep-onset REM periods (SOREMPs) on MSLT.
“…negative PSG-MSLT for narcolepsy (i.e., mean sleep latency>8 min or sleep onset REM…”
Narcolepsy type 1
Diagnosed using: CSF hypocretin-1 measurement.
“…systematically measuring CSF-HCRT1 in the presence of a negative PSG-MSLT identifies about 10% additional NT1…”
Treatment and management
What the research describes, not a recommendation. Treatment decisions belong with your clinician.
This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.
wake-promoting agents
Wake-promoting medicines are the mainstay for daytime sleepiness. Approved options include modafinil and armodafinil, pitolisant (which boosts histamine signaling), and solriamfetol. They reduce sleepiness but do not replace the missing orexin.
Used to help with: Narcolepsy type 1.
“…approved wake-promoting agents in…”
sodium oxybate
Sodium oxybate (and its lower-sodium and once-nightly forms) is taken at night and is one of the few treatments that improves both cataplexy and daytime sleepiness. Antidepressants are also used specifically to suppress cataplexy.
Used to help with: Narcolepsy type 1.
“…sodium oxybate (SXB) remains…”
Modafinil
modafinil is a wake-promoting medication used to treat narcolepsy; in a network meta-analysis of randomized trials it was effective compared with placebo.
Used to help with: Narcolepsy type 1.
“The final analysis included 13 RCTs with four drugs involved: modafinil/armodafinil, sodium oxybate (SXB), pitolisant, and solriamfetol, at different dosages or combinations. All drugs were effective in treating narcolepsy compared to placebo.”
Lower-sodium oxybate
lower-sodium oxybate is one of the approved medications for narcolepsy; it is a reduced-sodium form of oxybate that was among the wake-promoting agents studied in randomized trials.
Used to help with: Narcolepsy type 1.
“PURPOSE: Narcolepsy is a rare debilitating disorder for which multiple novel pharmacological options have been approved as treatment for the past few years.”
Orexin receptor 2 (OX2R) agonists
orexin receptor 2 (OX2R) agonists such as TAK-861 (oveporexton) are an investigational approach to narcolepsy type 1; if confirmed in large phase 3 trials, this class could become the first disease-modifying treatment rather than symptom relief.
Used to help with: Narcolepsy type 1.
“If validated in large-scale Phase 3 studies, TAK-861 could become the first disease-modifying therapy for NT1, representing a paradigm shift from symptomatic management to mechanism-based treatment.”
Antidepressants (for cataplexy)
antidepressants are among the current therapies for narcolepsy type 1; like stimulants and sodium oxybate they ease symptoms rather than correcting the underlying orexin deficiency.
Used to help with: Narcolepsy type 1.
“Narcolepsy type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, and disturbed nocturnal sleep, resulting from the loss of hypothalamic neurons that produce orexin. Current therapies, including stimulants, antidepressants, and sodium oxybate, primarily offer symptomatic relief without addressing the underlying orexin deficiency and often have safety or adherence limitations.”
Armodafinil
armodafinil, a wake-promoting medication closely related to modafinil, is used to treat narcolepsy and was effective compared with placebo in a network meta-analysis of randomized trials.
Used to help with: Narcolepsy type 1.
“The final analysis included 13 RCTs with four drugs involved: modafinil/armodafinil, sodium oxybate (SXB), pitolisant, and solriamfetol, at different dosages or combinations. All drugs were effective in treating narcolepsy compared to placebo.”
Pitolisant
pitolisant is a wake-promoting medication used to treat narcolepsy; in a network meta-analysis of randomized trials it was effective compared with placebo.
Used to help with: Narcolepsy type 1.
“The final analysis included 13 RCTs with four drugs involved: modafinil/armodafinil, sodium oxybate (SXB), pitolisant, and solriamfetol, at different dosages or combinations. All drugs were effective in treating narcolepsy compared to placebo.”
Solriamfetol
solriamfetol is a wake-promoting medication used to treat narcolepsy; in a network meta-analysis of randomized trials it was effective compared with placebo, and reduced excessive daytime sleepiness more than the other agents compared.
Used to help with: Narcolepsy type 1.
“The final analysis included 13 RCTs with four drugs involved: modafinil/armodafinil, sodium oxybate (SXB), pitolisant, and solriamfetol, at different dosages or combinations. All drugs were effective in treating narcolepsy compared to placebo.”
How to read the evidence labels
Where this comes from
This guide is built from 7 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.
Take it further
Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.